Anika Therapeutics Net Income 2006-2021 | ANIK

Anika Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Anika Therapeutics Annual Net Income
(Millions of US $)
2020 $-24
2019 $27
2018 $19
2017 $32
2016 $33
2015 $31
2014 $38
2013 $21
2012 $12
2011 $8
2010 $4
2009 $4
2008 $4
2007 $6
2006 $5
2005 $6
Anika Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $1
2021-06-30 $7
2021-03-31 $3
2020-12-31 $-16
2020-09-30 $-6
2020-06-30 $-8
2020-03-31 $6
2019-12-31 $4
2019-09-30 $9
2019-06-30 $9
2019-03-31 $5
2018-12-31 $8
2018-09-30 $8
2018-06-30 $10
2018-03-31 $-7
2017-12-31 $8
2017-09-30 $7
2017-06-30 $11
2017-03-31 $5
2016-12-31 $8
2016-09-30 $9
2016-06-30 $9
2016-03-31 $7
2015-12-31 $11
2015-09-30 $8
2015-06-30 $8
2015-03-31 $4
2014-12-31 $8
2014-09-30 $6
2014-06-30 $9
2014-03-31 $15
2013-12-31 $7
2013-09-30 $5
2013-06-30 $6
2013-03-31 $3
2012-12-31 $4
2012-09-30 $2
2012-06-30 $4
2012-03-31 $2
2011-12-31 $3
2011-09-30 $3
2011-06-30 $2
2011-03-31 $0
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $1
2009-09-30 $2
2009-06-30 $1
2009-03-31 $1
2008-12-31 $1
2008-09-30 $1
2008-06-30 $1
2008-03-31 $1
2007-12-31 $2
2007-09-30 $2
2007-06-30 $1
2007-03-31 $1
2006-12-31 $1
2006-09-30 $1
2006-06-30 $1
2006-03-31 $1
2005-12-31 $1
2005-09-30 $3
2005-06-30 $1
2005-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.550B $0.130B
Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90